Published On: Wed, Oct 19th, 2016

Mallinckrodt Plc (NYSE:MNK) Updated Broker Ratings


A number of investment brokers have recently updated their price targets on shares of Mallinckrodt plc (NYSE:MNK).

Most recent broker ratings

10/18/2016 – Mallinckrodt plc had its “outperform” rating reiterated by analysts at Wells Fargo. They now have a USD 83.5 price target on the stock.

10/17/2016 – Mallinckrodt plc had its “buy” rating reiterated by analysts at Deutsche Bank. They now have a USD 78 price target on the stock.

09/29/2016 – Mallinckrodt plc had its “buy” rating reiterated by analysts at Mizuho. They now have a USD 89 price target on the stock.

09/16/2016 – Mallinckrodt plc had its “outperform” rating reiterated by analysts at Leerink Swann. They now have a USD 92 price target on the stock.

09/06/2016 – Mallinckrodt plc had its “overweight” rating reiterated by analysts at Piper Jaffray. They now have a USD 105 price target on the stock.

08/25/2016 – Mallinckrodt plc had its “outperform” rating reiterated by analysts at BMO Capital Markets. They now have a USD 93 price target on the stock.

08/25/2016 – Mallinckrodt plc had its “neutral” rating reiterated by analysts at Goldman Sachs. They now have a USD 83 price target on the stock.

08/25/2016 – Mallinckrodt plc had its “overweight” rating reiterated by analysts at Barclays. They now have a USD 88 price target on the stock.

08/12/2016 – Stifel Nicolaus began new coverage on Mallinckrodt plc giving the company a “buy” rating. They now have a USD 95 price target on the stock.

08/03/2016 – Mallinckrodt plc had its “buy” rating reiterated by analysts at UBS. They now have a USD 92 price target on the stock.

08/03/2016 – Mallinckrodt plc had its “buy” rating reiterated by analysts at Jefferies. They now have a USD 95 price target on the stock.

08/02/2016 – Mallinckrodt plc had its “buy” rating reiterated by analysts at Guggenheim. They now have a USD 98 price target on the stock.

05/04/2016 – Mallinckrodt plc had its “neutral” rating reiterated by analysts at JP Morgan. They now have a USD 85 price target on the stock.

03/16/2016 – Mallinckrodt plc had its “outperform” rating reiterated by analysts at Northland Securities. They now have a USD 95 price target on the stock.

02/01/2016 – Mallinckrodt plc had its “neutral” rating reiterated by analysts at Nomura. They now have a USD 100 price target on the stock.

The share price of Mallinckrodt plc (NYSE:MNK) was down -1.22% during the last day of trading, with a day high of 65.21. 1871033 shares were traded during the last session.

The stock’s 50 day moving average is 71.99 and its 200 day moving average is 66.89. The stock’s market capitalization is 6.91B. Mallinckrodt plc has a 52-week low of 50.90 and a 52-week high of 85.83.

Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs. Its segments include Specialty Brands and Specialty Generics. The Specialty Brands segment produces and markets branded pharmaceutical products and therapies. The Specialty Generics segment produces and markets specialty generic pharmaceuticals and active pharmaceutical ingredient (API) consisting of biologics, medicinal opioids, synthetic controlled substances, acetaminophen and other active ingredients. Its product portfolio includes Acthar, Inomax, Ofirmev, Therakos immunotherapy, Hemostasis products and StrataGraft.